Allogene Therapeutics (ALLO) Operating Margin (2021 - 2024)

Allogene Therapeutics has disclosed Operating Margin across 4 years of filings, most recently posting 315927.27% for Q1 2024.

• Operating Margin for Q1 2024 came in at 315927.27%, up 1437939.0% year-over-year; the trailing twelve-month figure through Dec 2024 was 1241813.64% (down 89682732.0% YoY), and the FY2024 annual result was 1241813.64%, down 89682732.0% from the prior year.
• Operating Margin came in at 315927.27% for Q1 2024 at Allogene Therapeutics, up from 405280.95% in the prior quarter.
• In the past five years, Operating Margin ranged from a high of 2.26% in Q4 2021 to a low of 405280.95% in Q4 2023.
• The 4-year median for Operating Margin is 286345.45% (2023), against an average of 232707.56%.
• Peak annual rise in Operating Margin reached 4171705 bps in 2022, while the deepest fall reached 37075226 bps in 2022.
• Allogene Therapeutics' Operating Margin stood at 2.26% in 2021, then plunged by 16431036 bps to 370750.0% in 2022, then decreased by 9 bps to 405280.95% in 2023, then rose by 22 bps to 315927.27% in 2024.
• The last three Operating Margin figures came in at 315927.27% (Q1 2024), 405280.95% (Q4 2023), and 286345.45% (Q3 2023), per Business Quant data.